Sanofi to Halt MRNA Covid-19 Vaccine Development Despite Positive Trial Results -- Update
September 28 2021 - 5:12AM
Dow Jones News
By Cecilia Butini
Sanofi SA said Tuesday that it won't further advance the
development of a messenger-RNA vaccine against Covid-19 and would
instead focus on another type of shot, despite reporting positive
interim results in a phase 1/2 mRNA trial.
The French pharma major said it wouldn't make sense for it to
advance its mRNA vaccine into a phase 3 trial. "From a
public-health perspective, mRNA Covid vaccines are widely available
today and starting a placebo-controlled study in countries where
vaccines are available would be extremely challenging, so it does
not make sense for us to further advance our mRNA Covid vaccine
into Phase 3," a company spokesman said.
The company had said earlier Tuesday that a phase 1/2 trial for
a mRNA vaccine against the coronavirus showed neutralizing
antibodies in 91% to 100% of study participants two weeks after a
second injection.
Sanofi's work on Covid-19 will now be focused on a vaccine which
uses an adjuvanted recombinant protein technology and which it is
developing in partnership with GlaxoSmithKline PLC, it said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
September 28, 2021 04:57 ET (08:57 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024